Sign in
Canada Source-linked decisions Coverage checked

Canada Case Law

Search judgments by proposition, citation, court, judge or legal topic, then move directly into the source-grounded case analysis.

Courts on this page
2 court collections
Last checked

Canada decisions

Decisions matching the current search

Clear filters
Intellectual property 2026 FCA 71

McCain Foods Limited v. J.R. Simplot Company

The Federal Court did not commit a palpable and overriding error in its factual appreciation of expert evidence and common general knowledge; 'high electric field' in Claim 1 is properly understood by a skilled person at the date of publication to refer to electric fields in the range of about 2 to 200 V/cm, which excludes Simplot's pulsed electric field systems, and the appeal is dismissed.

  • Claim construction
  • Infringement
  • Invalidity
  • Utility
  • Person skilled in the art
  • Standard of review
Read case analysis
Patent law 2024 FC 424

Medexus Pharmaceuticals Inc. v. Accord Healthcare Inc.

The Federal Court held the asserted methotrexate patent claims invalid for obviousness, finding the inventive concept was concentration in a known subcutaneous context.

  • Obviousness
  • Claim construction
  • Ambiguity
  • Utility
  • Insufficiency
  • Remedies and damages
Read case analysis
Patent law 2023 FC 1684

Steelhead LNG (ASLNG) Ltd. v. ARC Resources Ltd.

Federal Court patent-invalidity counterclaim decision on an at-shore LNG patent: most claims were invalid, but claims 24, 25, 27, 28 and 29 were upheld.

  • Claim construction
  • Anticipation
  • Obviousness
  • Insufficiency
  • Overbreadth
  • Utility/sound prediction
Read case analysis
Patent law 2023 FCA 221

Sandoz Canada Inc. v. Janssen Inc.

The Federal Court correctly applied the Wellcome test for sound prediction and reasonably found the requirements met on the evidentiary record; omission of the Eli Lilly phrasing did not constitute an error of law; the appeal is dismissed and costs awarded to respondents in the agreed amount of $15,000.

  • Utility
  • Sound prediction
  • Obviousness
  • Invalidity
  • Overbreadth
  • Insufficiency
Read case analysis
Intellectual property 2022 FC 507

Angelcare Canada Inc. v. Munchkin Inc.

Patent infringement and validity dispute over diaper pail cassettes and pails, with purposive claim construction of clearance, chamfer, alignment, and movement features.

  • Claim construction
  • Infringement
  • Invalidity
  • Anticipation
  • Obviousness
  • Overbreadth
Read case analysis
Patent law 2022 FC 260

Allergan Inc. v. Apotex Inc.

The Federal Court held the ‘188 Patent valid but found Apotex’s APO-RISEDRONATE DR did not infringe because it was labelled for use with food only.

  • Claim construction
  • Anticipation
  • Obviousness
  • Utility
  • Sufficiency of disclosure
  • Overbreadth
Read case analysis
Patent law 2022 FCA 2

Pharmascience Inc. v. Teva Canada Innovation

The appeal is dismissed because the Trial Judge did not commit a reviewable error: the common general knowledge combined with the specification provided a sufficient factual basis and line of reasoning to support a sound prediction of utility for the claimed 40 mg thrice-weekly regimen, and the invention was not shown to be obvious as the person skilled in the art would not have been led directly and without difficulty to the claimed solution.

  • Utility
  • Sound prediction
  • Disclosure requirement
  • Obviousness
  • Standard of review
Read case analysis
Intellectual property 2021 FC 317

Merck Sharp & Dohme Corp. v. Wyeth LLC

Federal Court rules Merck’s action partially succeeds: the 363 patent claims are valid but limited to the 13 listed serotypes, while the formulation patents are largely invalid.

  • Patent validity
  • Anticipation
  • Obviousness
  • Claim construction
  • Enablement
  • Double patenting
Read case analysis
Patent law 2021 FC 367

Teva Canada Innovation v. Pharmascience Inc.

The Federal Court stayed a Patent Office re-examination pending final resolution of the related patent litigation, citing duplicative proceedings and risk of inconsistent outcomes.

  • Stay of proceedings
  • Re-examination
  • Issue estoppel
  • Obviousness
  • Utility
  • Balance of convenience
Read case analysis
Patent law 2021 FC 7

Janssen Inc. v. Apotex Inc.

The Federal Court held Janssen’s abiraterone acetate/prednisone patent claims obvious and invalid, dismissing the infringement action and the counterclaim.

  • Obviousness
  • Obvious to try
  • Utility
  • Sufficiency
  • Claim construction
  • Patentable subject matter
Read case analysis

About this LexChat collection

Canada decisions are organised by court, judge, legal area and indexed issue so a practitioner can move from a proposition to a citable authority with the surrounding context intact.